Brian Thompson, CEO of UnitedHealthcare, was recently shot and killed outside a Manhattan hotel. The gunman fled into Central Park and has remained at large. Thompson’s wife, Paulette, stated, “My husband had been getting threats before he was killed.” Thompson had sold $15.1 million in stock just days before news broke of a DOJ antitrust probe into UnitedHealthcare. Join us in this slideshow as we explore key information released about the ongoing investigation.
In recent years, UnitedHealthcare executives sold $101.5 million in shares overall, sparking rumors of insider trading. The DOJ is investigating whether UnitedHealthcare’s acquisitions illegally consolidated market dominance. Thompson’s stock sales are now under scrutiny.
The DOJ is also investigating UnitedHealthcare for antitrust violations, focusing on whether its acquisitions unlawfully consolidated market dominance.
Weinberg Center for Corporate Governance director Charles Elson stated, “Share sales by firm principals are typically scrutinized by a company’s general counsel, who can determine whether any additional disclosures to the market may be required before the trades are executed.”
UnitedHealthcare faced a massive data breach this year, exposing sensitive data for one-third of Americans. The breach cost the company $705 million in losses.
Thompson’s death, coupled with the DOJ probe and financial fallout, has left UnitedHealthcare facing significant legal and financial challenges.
Security expert Philip Klein stated that Thompson had likely refused personal protection despite receiving threats. Klein called his lack of security a “multi-layer failure.”
Investigators found bullet casings engraved with cryptic words linked to a book critical of the healthcare industry, suggesting the killer had a personal motive.
Klein questioned why Thompson, a high-profile CEO, was unguarded in NYC, calling it reckless. He dismissed the shooter as a professional, citing the evidence trail.